Abstract
There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
Keywords: β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Current Drug Delivery
Title:Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?
Volume: 12 Issue: 1
Author(s): David Van Ly and Brian G.G. Oliver
Affiliation:
Keywords: β2-agonists, desensitization, exacerbations, leukotrienes, prostaglandins, rhinovirus.
Abstract: There is an enormous drive to refine therapeutic designs and delivery systems, but in this review we ask if this is always the right direction? We choose to play devil's advocate, and argue that refining drug design is not always needed, and what is actually needed is a greater understanding of the biology of the disease. Here we focus on asthma and the β2-agonist group of bronchodilators as an example of how a class of therapeutic has been developed and continues to be developmentally refined. In this review, we define viralinduced exacerbations as the greatest cause of lung attacks and the most crucial time β2-agonist therapy is needed. We explore the reasons why β2-agonist therapy fails in patients with rhinovirus-induced exacerbations, and explain why further “engineered” β2-agonist therapies are likely to continue to fail in this subset of asthmatic population. We justify our perspective by returning to the biology that underlies the cause of disease and highlight the need for “more research” into alternative therapies for this population of asthmatic patients.
Export Options
About this article
Cite this article as:
Ly Van David and Oliver G.G. Brian, Do We Really Need to Keep Redesigning β2-agonists for the Management of Asthma?, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666140606112918
DOI https://dx.doi.org/10.2174/1567201811666140606112918 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Biology of the Interleukin-9 Pathway and its Therapeutic Potential for the Treatment of Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Influence of Ultrafine Particles Exposure on Asthma Exacerbation in Children: A Meta-Analysis
Current Drug Targets Clinical Characteristics and CT Imaging Features of COVID-19 on Admission: A Retrospective Study
Current Medical Imaging Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA
Current Pharmaceutical Design Platelet-Activating Factor (PAF): A Review of its Role in Asthma and Clinical Efficacy of PAF Antagonists in the Disease Therapy
Recent Patents on Inflammation & Allergy Drug Discovery High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Editorial: [Hot topic: Recent Advances in Drug Intolerance (Guest Editors: Jose A.G. Agundez)]
Current Drug Metabolism Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Globalization of Clinical Trials – Where are We Heading?
Current Clinical Pharmacology The Application of Phage Display in Allergy Research: Characterization of IgE, Identification of Allergens and Development of Novel Therapeutics
Current Pharmaceutical Biotechnology Diabetogenic Effects of Parthinium hysterophorous Induced Allergic Rhinitis
Inflammation & Allergy - Drug Targets (Discontinued) Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Cold Virus Fusion or Stopping Fusion Cold – Inhibitors of the Human Respiratory Syncytial Virus F Protein
Recent Patents on Anti-Infective Drug Discovery Transgenic Models in Allergic Responses
Current Drug Targets Subject Index To Volume 13
Current Medicinal Chemistry Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Active Symptom-Based Surveillance of Adverse Events Following Immunization Among Individuals Vaccinated with ChAdOx1 nCoV-19 Coronavirus Vaccine in a Tertiary Hospital of Kerala
Current Drug Safety